Loading clinical trials...
Loading clinical trials...
A Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Sleep Latency Effects of MK-6552 in Participants With Narcolepsy Type 1
Conditions
Interventions
MK-6552
Placebo
Locations
5
United States
Delta Waves, Inc. ( Site 0008)
Colorado Springs, Colorado, United States
Teradan Clinical Trials, LLC ( Site 0005)
Brandon, Florida, United States
NeuroTrials Research Inc ( Site 0006)
Atlanta, Georgia, United States
Bogan Sleep Consultants ( Site 0001)
Columbia, South Carolina, United States
FutureSearch Trials of Neurology ( Site 0004)
Austin, Texas, United States
Start Date
January 24, 2024
Primary Completion Date
October 23, 2024
Completion Date
October 23, 2024
Last Updated
March 20, 2025
NCT07363720
NCT06952699
NCT06809803
NCT06457945
NCT06555783
NCT06792708
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions